Rhabdomyolysis and statin therapy: relevance to the elderly.

  title={Rhabdomyolysis and statin therapy: relevance to the elderly.},
  author={Domenic A. Sica and Todd W. B. Gehr},
  journal={The American journal of geriatric cardiology},
  volume={11 1},
A recent debate has emerged as to the risk-benefit ratio of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). This debate has centered on the withdrawal of the HMG-CoA reductase inhibitor cerivastatin (Baycol). Its withdrawal was prompted by an unacceptably high rate of rhabdomyolysis associated with its use. The development of… CONTINUE READING